← Human Trials & Peer-Reviewed Studies
Differences in fibroid vascularity after three months of pre-treatment with leuprolide acetate or ulipristal acetate: A pilot study
Plain-language guide to PMID 31679806 (2020): pilot observational study study of Leuprolide in 23 women.
Key Facts
- PMID
- 31679806
- Journal
- European journal of obstetrics, gynecology, and reproductive biology
- Year
- 2020
- Study type
- Observational Study
- Authors
- Frijlingh M et al. (4 authors)
- DOI
- 10.1016/j.ejogrb.2019.08.002
What This Study Did, in Plain Language
What Was Tested
Researchers studied Leuprolide in this observational study publication.
To investigate differences in volume and fibroid vascularity expressed in vascular index after three months of (pre-)treatment with leuprolide acetate (LPA) or ulipristal acetate (UPA).
Who Took Part
According to the abstract, 23 women were involved.
The age groups tagged for this paper are adults, women only.
Prospective pilot study of 23 premenopausal women with uterine fibroids.
Patients who started with LPA or UPA and had at least one fibroid with a size between 3 and 12 cm, were included consecutively.
How the Study Was Run
In design terms this was a pilot study.
It is described as a pilot, a small early test of whether a larger Leuprolide study would be practical.
The timeline in the abstract includes three months.
Per patient one fibroid was evaluated.
The ultrasound was performed at baseline and after three months using LPA or UPA using a standardized protocol. 3D scans were evaluated using VOCAL software to calculate outcomes of volume, vascular index (VI) without shell ("shell off") and of the inner shell.
What Was Measured
Topics PubMed links to this paper include Antineoplastic Agents, Hormonal, Leiomyoma, Leuprolide, Neovascularization, Pathologic, Netherlands, Norpregnadienes and Pilot Projects.
The authors tagged it with the keywords Fibroid, Leuprolide acetate, Ulipristal acetate, Ultrasound, Vascular index and Vascularity.
What This Means in Plain Language
The paper is a pilot study of Leuprolide in 23 women over three months.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2020 (European journal of obstetrics, gynecology, and reproductive biology), a journal based in Ireland.
More context: the Leuprolide compound page, all human trials.
Our Notes on the Compound
Leuprolide: A 9-amino-acid GnRH analog (Lupron, Eligard) that lowers sex-hormone levels with ongoing use; used in prostate cancer, endometriosis and early puberty.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.